D. E. Shaw & Co. Inc. Sells 149,495 Shares of PetMed Express, Inc. (NASDAQ:PETS)

D. E. Shaw & Co. Inc. decreased its stake in PetMed Express, Inc. (NASDAQ:PETS - Free Report) by 46.5% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 171,987 shares of the company's stock after selling 149,495 shares during the period. D. E. Shaw & Co. Inc. owned 0.83% of PetMed Express worth $829,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Arrowstreet Capital Limited Partnership increased its stake in shares of PetMed Express by 26.5% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 513,381 shares of the company's stock worth $2,474,000 after purchasing an additional 107,614 shares during the last quarter. Metavasi Capital LP grew its holdings in PetMed Express by 48.5% during the fourth quarter. Metavasi Capital LP now owns 340,302 shares of the company's stock valued at $1,640,000 after purchasing an additional 111,194 shares during the period. Geode Capital Management LLC increased its position in PetMed Express by 1.6% in the fourth quarter. Geode Capital Management LLC now owns 224,788 shares of the company's stock worth $1,084,000 after buying an additional 3,558 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in shares of PetMed Express by 2.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 216,812 shares of the company's stock valued at $1,045,000 after buying an additional 4,410 shares during the period. Finally, JPMorgan Chase & Co. raised its stake in shares of PetMed Express by 355.5% in the fourth quarter. JPMorgan Chase & Co. now owns 106,954 shares of the company's stock valued at $516,000 after buying an additional 83,473 shares during the period. 73.33% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at PetMed Express

In other news, major shareholder Silvercape Investments Ltd purchased 7,401 shares of PetMed Express stock in a transaction dated Tuesday, May 20th. The stock was purchased at an average cost of $3.95 per share, for a total transaction of $29,233.95. Following the transaction, the insider now directly owns 2,307,719 shares of the company's stock, valued at approximately $9,115,490.05. This trade represents a 0.32% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Sandra Yvette Campos sold 60,463 shares of the company's stock in a transaction on Wednesday, April 30th. The stock was sold at an average price of $3.31, for a total transaction of $200,132.53. Following the completion of the transaction, the chief executive officer now directly owns 578,524 shares in the company, valued at approximately $1,914,914.44. The trade was a 9.46% decrease in their position. The disclosure for this sale can be found here. Insiders own 1.10% of the company's stock.

Wall Street Analysts Forecast Growth

PETS has been the subject of several research reports. Wall Street Zen downgraded PetMed Express from a "buy" rating to a "hold" rating in a research note on Wednesday, May 7th. Morgan Stanley cut their target price on shares of PetMed Express from $3.50 to $3.20 and set an "underweight" rating for the company in a research report on Thursday, April 17th.

PetMed Express Price Performance

PETS stock remained flat at $3.78 during midday trading on Thursday. 36,882 shares of the company's stock were exchanged, compared to its average volume of 272,145. The stock has a market capitalization of $78.08 million, a price-to-earnings ratio of 378.38 and a beta of 0.76. The firm has a 50 day moving average price of $3.57 and a 200-day moving average price of $4.37. PetMed Express, Inc. has a 1-year low of $2.90 and a 1-year high of $6.85.

About PetMed Express

PetMed Express, Inc, together with its subsidiaries, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, health products, and other supplies for dogs, cats, and horses. It offers non-prescription medications and supplies, such as flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and household pet supplies; and prescription medications, including heartworm preventatives, flea and tick preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes.